Other

Gilead in $21 bn deal for Immunomedics

US pharmaceutical giant Gilead Sciences confirmed Sunday that it is buying American biotech firm Immunomedics, which makes a breast cancer drug, for $21 billion.

Oncology & Cancer

Venom from honeybees found to kill aggressive breast cancer cells

Using the venom from 312 honeybees and bumblebees in Perth Western Australia, Ireland and England, Dr. Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia, tested the effect ...

Oncology & Cancer

Tailoring treatment for triple-negative breast cancer

Immunotherapies have revolutionized treatment for people with a variety of cancers. But when given to those with triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, less than 20% respond.

page 1 from 20